On September 27, 2023 MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that two abstracts have been accepted for poster presentations at the 38th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, the world-leading event in immunotherapy, scheduled to be held from November 1-5, 2023, in San Diego, California, U.S.A (Press release, MaaT Pharma, SEP 27, 2023, View Source [SID1234635455]). This is the first time that the Company will present non-clinical data in immuno-oncology which include its Artificial Intelligence (AI) screening approach and in vitro results for the first member of the new generation MaaT03X range of products dedicated to improving responses in immunotherapy for patients with solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Immune checkpoint inhibitor (ICI) therapies have become the standard of care for treating solid tumors. However, only around 25% to 35% of patients respond to the treatment. Simultaneously, numerous studies have indicated that immune homeostasis and the diversity and richness of gut microbiota could improve the response to ICI treatment[1]. This research opens promising new possibilities for enhancing cancer treatment. The Company has chosen to pursue this avenue, focusing on the potential of the gut microbiome’s diversity, richness, and its key functional networks, which could be a game-changer in the field of immuno-oncology in the coming years. In this context, the company has developed an AI-driven program to select the most effective tailor-made microbiome for specific indications in multiple areas, with a first focus on ICI.
SITC Poster Presentations details:
Title: Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
Abstract Number: 1321
Title: Robust Machine Learning (ML) approach for Screening Microbiome Ecosystem Therapies (MET) Drug Candidates in combination with Immune Checkpoint Inhibitors
Abstract Number: 1304
In line with the embargo policy of the congress, additional details on data scheduled to be presented at the 2023 edition of SITC (Free SITC Whitepaper) will be released on October 31st, 2023.